Clinical Trial Update: Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing cangrelor (Kengreal) with ticagrelor (Brilinta) for early platelet inhibition in ST-segment elevation myocardial infarction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• St-segment Elevation Myocardial Infarction

Drugs mentioned

• BRILINTA (ticagrelor)
• Kengreal (cangrelor)

Snippet

Sponsor: University of Aarhus | Conditions: Acute Coronary Syndrome, Myocardial Infarction | Phase 4 | Status: UNKNOWN